Verona Pharma plc (VRNA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
VRNA Chart
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Verona Pharma plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RC Ryan Cahill Cahill Wealth Management LLC | 8,060 | $242.82 | $241.8 | -$1.02 | -0.42% |
 Kerry Kourepenos Cutter Capital Management, LP | 160,000 | $10.16M | $10.16M | - | - |
Verona Pharma plc (VRNA) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Verona Pharma plc Profile
| - Industry | - Sector | David S. Zaccardelli CEO | NASDAQ (NMS) Exchange | 925050106 CUSIP |
| GB Country | 209 Employees | - Last Dividend | - Last Split | 27 Apr 2017 IPO Date |
Overview
Verona Pharma plc is a pioneering clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies aimed at treating respiratory diseases that currently lack adequate medical solutions. With its roots firmly planted since its incorporation in 2005, Verona Pharma has established its headquarters in the vibrant city of London, United Kingdom. The company has positioned itself as a leader in the respiratory disease sector by focusing on addressing the critical unmet needs within this therapeutic area.
Products and Services
- Ensifentrine as a Dual-Action Therapeutic Agent
Verona Pharma's flagship product candidate, ensifentrine, stands at the forefront of its clinical pipeline. This compound is uniquely characterized by its dual inhibition of two key enzymes, phosphodiesterase (PDE) 3 and PDE4. This dual action allows ensifentrine not only to act as a potent bronchodilator but also as an anti-inflammatory agent, combining two essential therapeutic effects into a single compound. Currently, ensifentrine is undergoing Phase 3 clinical trials, demonstrating its potential effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
- Ensifentrine in Multiple Formulations
In efforts to maximize its accessibility and efficacy for a broad range of patients, Verona Pharma is developing ensifentrine in three distinct formulations. These include:
- A nebulizer formulation, designed for home use to deliver medication directly to the lungs through the aid of a nebulizing device.
- A dry powder inhaler (DPI), offering a convenient and portable option for patients requiring on-the-go treatment.
- A pressurized metered-dose inhaler (pMDI), serving as another portable inhalation device but with the added advantage of a pressurized aerosol for easy administration.
Each of these formulations is being developed to ensure that patients with varying preferences and medical requirements can benefit from the therapeutic potential of ensifentrine.
